Table 3.

Review of literature, daratumumab monotherapy in adult patients with primary and secondary AIHA (non–stem cell transplantation setting)

age/sex	Disease	Previous treatments	Daratumumab schedule	Best response	Time to response Hb PR/CR∗ and acrocyanosis	Duration of response	Reference
60, F	wAIHA	Steroids, rituximab azathioprine	4× 16 mg/kg IV weekly	PR	10 wk	5 mo	19
44, F	wAIHA	Steroids, rituximab, IVIG, HSA, splenectomy, cylcosporine, mycophenolate	6× 16 mg/kg IV weekly + 6× 16 mg/kg IV maintenance	CR	na	5 mo	17
55, F	wAIHA	Steroids, rituximab	6× 16 mg/kg IV weekly	CR	na	2 mo	17
55, F†	wAIHA	Steroids	6× 16 mg/kg IV weekly	CR	1 wk	Relapse after 9 mo	13
55, F†	wAIHA	Steroids, azathioprine, cyclosporine, everolimus, bortezomib	8× 16 mg/kg IV weekly + 3× 2-weekly 16mg/kg IV	No response	No response	-	13
64,F	wAIHA	Prednison, rituximab, splenectomy	8× 16 mg/kg IV weekly	CR	Na	Ongoing response after 20 mo	20
56, M†	cAIHA	Steroids, rituximab, bortezomib, cyclophosfamide, lenalidomide	8× weekly 16mg/kg IV + 16× 2-weekly 16mg/kg IV + monthly 16mg/kg IV maintenance	CR Hb PR acrocyanosis	2 wk 2 wk improvement of acrocyanosis	Ongoing response after 10 mo	22
59, M†	cAIHA	Steroids, rituximab, EPO bortezomib	8× weekly 16mg/kg IV + 16× 2-weekly 16mg/kg IV + monthly 16mg/kg IV maintenance	PR	12 wk	Ongoing after 16 mo	12
73, M	cAIHA	Rituximab, ibrutinib, bendamustine	Na, maintenance therapy ongoing at 15 mo	PR	na	Ongoing response after 15 mo	20
64, F	cAIHA	Rituximab	8× weekly 16mg/kg IV + 8× 2-weekly 16mg/kg IV + monthly 16mg/kg IV maintenance Combination with HSA	CR	5 mo PR 6 mo CR	Ongoing response after 8 mo	21

CR, complete response; F, female; HSA, haematopoiesis-stimulating agents; M, male; PR, partial response;

^∗Hemoglobin (Hb) response was considered partial (PR; Hb, 10-12 g/dL) or complete (CR, Hb > 12 g/dL).

^†Case included and updated in our case series.